Cite
HARVARD Citation
Merle, P. et al. (n.d.). O-011Assessment of tumor response, AFP response, and time to progression in the phase 3 CELESTIAL trial of cabozantinib versus placebo in advanced hepatocellular carcinoma (HCC). Annals of oncology. p. . [Online].